| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac2c17e532220d91aca9a28ef60f178b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6951
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D235-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 |
| filingDate |
2012-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfdf8317c829d744ec12cb318344b493
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf1c46009ead1a48e26f3ea68eeaa5cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a16f5e6f6b1769725b26ec890e025e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eaccaa7fbef0f4e556e72ab0cde43c84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adcb040c02310ccfae48aa89826799f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a44b504505eaeb7aae8b71f38c98b967 |
| publicationDate |
2017-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EA-028413-B1 |
| titleOfInvention |
PHARMACEUTICAL COMPOSITIONS |
| abstract |
The invention relates to a pharmaceutical composition for treating a neoplastic disease or an immune disease comprising a cyclodextrin and a compound of formula (III) or a pharmaceutically acceptable salt thereof. The composition may also contain a pH adjusting agent. The invention also relates to a pharmaceutical dosage form containing a composition in which the pH adjusting agent is included, the compound of formula (III) being contained in an amount of 5-500 mg. The invention also relates to a lyophilized formulation of said composition packaged in a vial or other pharmaceutically acceptable container. The invention also relates to a method of treating a neoplastic disease or an immune disease, comprising administering an effective amount of said composition to an individual in need of treatment. |
| priorityDate |
2011-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |